Article: Kimball Genetics, Inc. Launches the Warfarin Sensitivity DNA Test for Research.

DENVER, Nov. 14 /PRNewswire/ -- Kimball Genetics, Inc. is pleased to announce today the launch of its Warfarin Sensitivity DNA Test for research/investigational purposes. Warfarin is the most frequently prescribed oral anticoagulant used for the prevention and treatment of thromboembolic events. However, it is a difficult drug to manage due to its narrow therapeutic range and inconsistent patient response resulting from inter-individual variability. Genetic information available from the new pharmacogenomic test will help predict response. The Warfarin Sensitivity DNA Test determines the presence of specific variations in the CYP2C9 and VKORC1 genes that confer ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!